Translational Research Institute, Henan Provincial Peoples Hospital, Academy of Medical Science, Zhengzhou UniversityZhengzhouP.R. China.
School of Biomedical Sciences and Pharmacy, The University of NewcastleCallaghan, NSWAustralia.
Oncol Res. 2020 Sep 1;28(4):385-398. doi: 10.3727/096504020X15861709922491. Epub 2020 Apr 6.
The deubiquitinase cylindromatosis (CYLD) functions as a tumor suppressor inhibiting cell proliferation in many cancer types including melanoma. Here we present evidence that a proportion of melanoma cells are nonetheless addicted to CYLD for survival. The expression levels of CYLD varied widely in melanoma cell lines and melanomas in vivo, with a subset of melanoma cell lines and melanomas displaying even higher levels of CYLD than melanocyte lines and nevi, respectively. Strikingly, although short hairpin RNA (shRNA) knockdown of CYLD promoted, as anticipated, cell proliferation in some melanoma cell lines, it reduced cell viability in a fraction of melanoma cell lines with relatively high levels of CYLD expression and did not impinge on survival and proliferation in a third type of melanoma cell lines. The decrease in cell viability caused by CYLD knockdown was due to induction of apoptosis, as it was associated with activation of the caspase cascade and was abolished by treatment with a general caspase inhibitor. Mechanistic investigations demonstrated that induction of apoptosis by CYLD knockdown was caused by upregulation of receptor-interacting protein kinase 1 (RIPK1) that was associated with elevated K63-linked polyubiquitination of the protein, indicating that CYLD is critical for controlling RIPK1 expression in these cells. Of note, microRNA (miR) profiling showed that miR-99b-3p that was predicted to target the 3-untranslated region (3-UTR) of the CYLD mRNA was reduced in melanoma cell lines with high levels of CYLD compared with melanocyte lines. Further functional studies confirmed that the reduction in miR-99b-3p expression was responsible for the increased expression of CYLD in a highly cell line-specific manner. Taken together, these results reveal an unexpected role of CYLD in promoting survival of a subset of melanoma cells and uncover the heterogeneity of CYLD expression and its biological significance in melanoma.
去泛素化酶 CYLD 作为一种肿瘤抑制因子,在包括黑色素瘤在内的多种癌症类型中抑制细胞增殖。在这里,我们提供的证据表明,一部分黑色素瘤细胞仍然依赖 CYLD 来生存。黑色素瘤细胞系和体内黑色素瘤的 CYLD 表达水平差异很大,其中一些黑色素瘤细胞系和黑色素瘤的 CYLD 表达水平甚至高于黑素细胞系和痣。引人注目的是,尽管短发夹 RNA (shRNA) 敲低 CYLD 促进了一些黑色素瘤细胞系中预期的细胞增殖,但它降低了具有相对高水平 CYLD 表达的一部分黑色素瘤细胞系的细胞活力,并且对第三类黑色素瘤细胞系的生存和增殖没有影响。CYLD 敲低导致的细胞活力下降是由于细胞凋亡的诱导,因为它与半胱天冬酶级联的激活有关,并且可以被一般半胱天冬酶抑制剂的治疗所消除。机制研究表明,CYLD 敲低诱导的细胞凋亡是由受体相互作用蛋白激酶 1 (RIPK1) 的上调引起的,这与该蛋白的 K63 连接多泛素化的升高有关,表明 CYLD 在这些细胞中对控制 RIPK1 表达至关重要。值得注意的是,miRNA (miR) 谱分析表明,miR-99b-3p 预测靶向 CYLD mRNA 的 3'非翻译区 (3'UTR),在具有高水平 CYLD 的黑色素瘤细胞系中与黑素细胞系相比减少。进一步的功能研究证实,miR-99b-3p 表达的减少导致 CYLD 的表达以高度细胞系特异性的方式增加。总之,这些结果揭示了 CYLD 在促进一部分黑色素瘤细胞生存中的意外作用,并揭示了 CYLD 表达的异质性及其在黑色素瘤中的生物学意义。